Company 10x Genomics, Inc.

Equities

TXG

US88025U1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 05/03/2026 GMT			5-day change	1st Jan Change
21.64 ^USD	-3.26%		-2.21%	+32.68%

02-20	UBS Adjusts Price Target on 10x Genomics to $20 From $14, Maintains Neutral Rating	MT
02-12	10x Genomics, Inc., Q4 2025 Earnings Call, Feb 12, 2026

Business description: 10x Genomics, Inc.

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Number of employees: 1,178

Sales by Activity: 10x Genomics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Scientific & Technical Instruments	490M	516M	619M	611M	643M

See all business segments

Geographical breakdown of sales: 10x Genomics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	258M	285M	360M	334M	347M
Europe, Middle East and Africa	108M	117M	142M	160M	162M
China	74.92M	59.56M	50.96M	57.3M	70.26M
Asia-Pacific (Excluding China)	42.09M	46M	52.29M	45.96M	52.07M
Americas (Excluding United States)	6.71M	8.79M	13.1M	13.45M	12.26M

See all geographic segments

Executive Committee: 10x Genomics, Inc.

Manager	Title	Age	Since
Serge Saxonov CEO	Chief Executive Officer	49	01/07/2012
Ben Hindson PSD	President	51	30/09/2012
Adam Taich DFI	Director of Finance/CFO	51	11/08/2024
Michael Schnal-Levin CTO	Chief Tech/Sci/R&D Officer	-	31/12/2012
Cassie Corneau IRC	Investor Relations Contact	-	31/10/2020

See 10X GENOMICS, INC. governance

Composition of the Board of Directors: 10x Genomics, Inc.

Director	Title	Age	Since
Ben Hindson BRD	Director/Board Member	51	01/07/2012
Serge Saxonov BRD	Director/Board Member	49	01/07/2012
John Stuelpnagel CHM	Chairman	68	31/07/2013
Sridhar Kosaraju BRD	Director/Board Member	48	31/03/2019
Shehnaaz Suliman BRD	Director/Board Member	54	31/07/2019
Kim Popovits BRD	Director/Board Member	67	25/03/2020
Alan Mateo BRD	Director/Board Member	64	17/06/2024
Sarah Teichmann BRD	Director/Board Member	50	09/07/2024

Composition of the Board of Directors

Shareholders: 10x Genomics, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 11.18 %	13,017,914	11.18 %	263 M $
ARK Investment Management LLC 10.88 %	12,667,369	10.88 %	256 M $
Fidelity Management & Research Co. LLC 10.23 %	11,917,482	10.23 %	241 M $
BlackRock Advisors LLC 7.975 %	9,289,202	7.975 %	188 M $
SUMITOMO MITSUI TRUST GROUP, INC. 4.715 %	5,492,189	4.715 %	111 M $

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 24.21 %	4,870,733	24.21 %	98 M $
Serge Saxonov 15.07 %	3,031,865	15.07 %	61 M $
Ben Hindson 14.91 %	3,000,000	14.91 %	61 M $
John Stuelpnagel 10.47 %	2,105,736	10.47 %	43 M $

List of 10X GENOMICS, INC. shareholders

Company details: 10x Genomics, Inc.

10X Genomics, Inc.

6230 Stoneridge Mall Road

94588, Pleasanton

+925 401 7300

http://www.10xgenomics.com

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
10X GENOMICS, INC.	-3.26%	-2.21%	+97.99%	-57.57%	2.76B
BIOMÉRIEUX	-0.10%	-4.80%	-16.86%	+2.12%	13B
GUARDANT HEALTH, INC.	-0.47%	-5.50%	+117.02%	+188.59%	12.14B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.71%	+0.13%	-14.40%	-12.48%	5.93B
CARIS LIFE SCIENCES, INC.	-3.22%	-0.10%	-	-	5.43B
LANTHEUS HOLDINGS, INC.	-1.97%	+1.17%	-24.05%	+4.62%	4.93B
DIASORIN S.P.A.	+0.29%	-3.20%	-27.76%	-38.85%	4.29B
ANDON HEALTH CO., LTD.	-1.41%	+14.85%	+20.93%	+3.63%	3.06B
AUTOBIO DIAGNOSTICS CO., LTD.	-0.41%	-4.92%	-17.62%	-45.29%	2.85B
VCANBIO CELL & GENE ENGINEERING CORP., LTD	+1.04%	+2.74%	+34.40%	+54.34%	1.86B
Average	-1.02%	+0.20%	+18.85%	+11.01%	5.63B
Weighted average by Cap.	-0.87%	-0.99%	+24.15%	+37.85%